Study of ECF Chemotherapy in Pancreatic Cancer
Author Information
Author(s): TRJ Evans, FJ Lofts, JL Mansil, JP Glees, AG Dalgleish, MJ Knight
Primary Institution: St George's Hospital Medical School
Hypothesis
The ECF regimen can improve survival in patients with inoperable pancreatic cancer.
Conclusion
The ECF regimen can prolong survival in patients with locally advanced or metastatic pancreatic cancer, but it is associated with considerable toxicity.
Supporting Evidence
- Objective tumour responses were documented in five (17.3%) patients.
- Patients with stable disease or partial response had a median survival of 253 days.
- Grade 3/4 toxicity included alopecia in 56% of patients and neutropenic sepsis in 10 patients.
Takeaway
This study tested a new chemotherapy combination for pancreatic cancer and found it can help some patients live longer, but it can also cause serious side effects.
Methodology
Patients with inoperable pancreatic cancer received continuous infusion of 5-FU, cisplatin, and epirubicin, and their responses and toxicities were evaluated.
Potential Biases
Potential bias due to lack of randomization and the observational nature of the study.
Limitations
The study had a small sample size and high toxicity rates, which may limit the generalizability of the results.
Participant Demographics
Mean age was 59 years, with a range of 37-75 years; 21 males and 14 females.
Statistical Information
P-Value
0.01
Statistical Significance
p=0.01
Want to read the original?
Access the complete publication on the publisher's website